Healthequity, Inc. (HQY) · Aug 27, 2026 · Earnings

HealthEquity beats EPS and raises guidance as revenue growth cools

Beat — Non-GAAP EPS $1.24 vs ~$1.20 consensus

HealthEquity delivered a narrow earnings beat and lifted FY27 targets, but revenue came in just below consensus and buybacks drained cash.

The quarter cleared the main earnings bar, but not on revenue. Published consensus was roughly $1.20 for non-GAAP EPS and $352.7 million for revenue; HealthEquity delivered $1.24 and $350.7 million, respectively. That makes this an earnings beat driven by profitability, with a modest top-line miss rather than a clean across-the-board upside surprise.

MetricQ2 FY27Q2 FY26Market comparison
Revenue$350.7M (Financial Highlights)$325.8M (Financial Highlights)~$352.7M consensus
Non-GAAP diluted EPS$1.24 (Non-GAAP reconciliation)$1.08 (Non-GAAP reconciliation)~$1.20 consensus
Adjusted EBITDA$167.0M (Adjusted EBITDA reconciliation)$151.1M (Adjusted EBITDA reconciliation)—
Adjusted EBITDA margin48% (Financial Highlights)46% (Financial Highlights)—
FY27 revenue guidance$1.411B–$1.421B (Outlook)Prior: $1.410B–$1.420B—
FY27 Adjusted EBITDA guidance$628M–$636M (Outlook)Prior: $625M–$633M—

Profitability was the genuine upside. Non-GAAP EPS rose 15% year over year to $1.24, while Adjusted EBITDA increased 11% to $167.0 million and margin expanded to 48%. The result suggests cost leverage and execution more than demand acceleration were responsible for the beat.

The underlying franchise remained healthy, but growth was not accelerating everywhere. HSA assets grew 14% to $37.9 billion, HSA accounts increased 8% to 10.7 million, and new HSAs from sales rose 24% to 202,000. However, total CDB accounts declined 2% year over year to 7.0 million, while total revenue grew 8%, below the prior-year quarter's 9% growth rate.

The guidance raise is real but modest, so much of the direction was already known. Management lifted the midpoint of FY27 revenue guidance by only $1 million and the Adjusted EBITDA midpoint by $3 million from the outlook issued after Q1. The better signal is that the company raised targets despite the slight quarterly revenue miss; the limitation is that the revision does not materially reset the year's earnings framework.

Capital returns were aggressive, but cash fell sharply. HealthEquity repurchased $231.1 million of stock in the first half, including $108.1 million in Q2, while ending cash declined to $256.0 million from $318.9 million at January 31. (Cash Flow statement) Debt also remained substantial at $931.1 million. (Condensed consolidated balance sheets) That does not undermine the earnings beat, but it means the stronger per-share result partly benefits from a shrinking share count and comes with less cash on the balance sheet.

What to watch next

Q3 FY27 earnings report, expected late November 2026

Original filing on SEC EDGAR

More Healthequity, Inc. news

HealthEquity beats EPS and raises guidance as revenue growth cools | HQY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.